• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

前列腺癌筛查：一项关于游离及总前列腺特异性抗原的研究

Screening for prostate cancer: a study on the free and total prostate specific antigen.

作者信息

Mediu Ridvana, Rama Ariol, Mediu Naim

机构信息

Faculty of Applied Science, Medical Science Department, University College LOGOS, Tirana, Albania.

General surgeon. Surgery Service, Regional Hospital, Durres, Albania.

出版信息

Discoveries (Craiova). 2021 Dec 31;9(4):e139. doi: 10.15190/d.2021.18. eCollection 2021 Oct-Dec.

DOI:10.15190/d.2021.18
PMID:35359347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8960002/
Abstract

BACKGROUND

A variety of biomarkers have been developed to monitor growth of cancerous diseases and to detect them at an early stage. Prostate-specific antigen (PSA) is a valuable prostate cancer biomarker that is now widely used for population screening, diagnosis, and monitoring of patients with prostate cancer. Other factors than prostate cancer can cause elevation of PSA levels therefore, free prostate specific antigen measurements in serum have been proposed in order to improve the specificity of laboratory identification of prostate cancer.

AIM

The aim of our study was to evaluate the diagnostic significance of both total PSA and Free PSA in discriminating prostate cancer from other prostate diseases.

MATERIALS AND METHODS

Our study group consisted of 1201 males admitted at outpatient clinic aged between 35 and 84 years old (mean age 63 years). All laboratory measurements were performed on serum samples. The data were statistically analyzed by using descriptive statistics for Windows.

RESULTS

The mean total PSA concentration evaluated among 1038 patients was 16.17 ng/mL whereas only Free PSA concentration was evaluated in 163 serum samples and resulted in a mean value of 2.67 ng/ml. In order to calculate the correlation between total and free PSA, data among 69 /1038 patients were further analyzed through statistical program software package for data analysis.

CONCLUSIONS

Measuring serum free PSA concentrations along with PSA concentrations may provide higher accuracy for detecting prostate cancer and might eliminate unnecessary biopsies in the men with PSA of more than 4.0 ng/mL.

摘要

背景

已开发出多种生物标志物来监测癌症疾病的发展并在早期进行检测。前列腺特异性抗原（PSA）是一种有价值的前列腺癌生物标志物，目前广泛用于人群筛查、诊断和监测前列腺癌患者。然而，除前列腺癌外的其他因素也可导致PSA水平升高，因此，有人提出检测血清中的游离前列腺特异性抗原，以提高前列腺癌实验室鉴定的特异性。

目的

我们研究的目的是评估总PSA和游离PSA在鉴别前列腺癌与其他前列腺疾病中的诊断意义。

材料和方法

我们的研究组由1201名年龄在35至84岁（平均年龄63岁）之间的门诊男性组成。所有实验室检测均在血清样本上进行。使用Windows的描述性统计对数据进行统计分析。

结果

在1038名患者中评估的平均总PSA浓度为16.17 ng/mL，而仅在163份血清样本中评估了游离PSA浓度，其平均值为2.67 ng/ml。为了计算总PSA和游离PSA之间的相关性，通过数据分析统计软件包对69/1038名患者的数据进行了进一步分析。

结论

同时测量血清游离PSA浓度和PSA浓度可能为检测前列腺癌提供更高的准确性，并可能消除PSA大于4.0 ng/mL的男性不必要的活检。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/ce561b0cba6c/discoveries-09-139-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/200ca21f1154/discoveries-09-139-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/084a6cf3d828/discoveries-09-139-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/cab487791589/discoveries-09-139-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/a5f421a4b048/discoveries-09-139-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/9b7ffc38a33a/discoveries-09-139-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/a64968ae2993/discoveries-09-139-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/a3712f30bb76/discoveries-09-139-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/92b24df3ce01/discoveries-09-139-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/ce561b0cba6c/discoveries-09-139-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/200ca21f1154/discoveries-09-139-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/084a6cf3d828/discoveries-09-139-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/cab487791589/discoveries-09-139-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/a5f421a4b048/discoveries-09-139-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/9b7ffc38a33a/discoveries-09-139-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/a64968ae2993/discoveries-09-139-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/a3712f30bb76/discoveries-09-139-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/92b24df3ce01/discoveries-09-139-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f237/8960002/ce561b0cba6c/discoveries-09-139-g009.jpg

相似文献

1
Screening for prostate cancer: a study on the free and total prostate specific antigen.前列腺癌筛查：一项关于游离及总前列腺特异性抗原的研究
Discoveries (Craiova). 2021 Dec 31;9(4):e139. doi: 10.15190/d.2021.18. eCollection 2021 Oct-Dec.
2
[Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].[前列腺特异性抗原在确定初次前列腺活检指征中的预后意义]
Urologiia. 2018 Jul(3):92-97.
3
Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.游离前列腺特异性抗原百分比的测定有助于避免对直肠检查正常且总前列腺特异性抗原为4 - 10 ng/ml的男性进行不必要的活检。
Eur Urol. 2000 Mar;37(3):289-96. doi: 10.1159/000052358.
4
Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.游离/总前列腺特异性抗原（f/t PSA）比值在前列腺癌诊断中的应用
Dis Markers. 2003;19(6):287-92. doi: 10.1155/2004/913870.
5
Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.游离前列腺特异性抗原百分比的诊断价值：一项基于人群的筛查研究的回顾性分析，重点关注前列腺特异性抗原水平低于3.0 ng/mL的男性。
Urology. 1999 May;53(5):945-50. doi: 10.1016/s0090-4295(98)00640-2.
6
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.评估游离血清前列腺特异性抗原百分比以提高前列腺癌筛查的特异性。
JAMA. 1995 Oct 18;274(15):1214-20.
7
Prostate specific antigen density of the transition zone for early detection of prostate cancer.用于早期检测前列腺癌的移行区前列腺特异性抗原密度
J Urol. 1998 Aug;160(2):411-8; discussion 418-9.
8
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.在总前列腺特异性抗原水平为2至4纳克/毫升范围内的游离前列腺特异性抗原百分比，与4至10纳克/毫升范围内相比，并不会显著增加检测临床显著性前列腺癌所需的活检次数。
J Urol. 2002 Aug;168(2):504-8.
9
Prostate cancer screening in Tyrol, Austria: experience and results.奥地利蒂罗尔州的前列腺癌筛查：经验与结果
Eur Urol. 1999;35(5-6):523-38. doi: 10.1159/000019893.
10
[The significance of early detection for prostate cancer in mass screening].[早期检测在前列腺癌群体筛查中的意义]
Nihon Hinyokika Gakkai Zasshi. 2001 Jan;92(1):23-9. doi: 10.5980/jpnjurol1989.92.23.

引用本文的文献

1
The Clinical Predictors of Malignancy in the Prostate Gland and Their Correlation With Prostate-Specific Antigen (PSA) Levels.前列腺癌的临床预测指标及其与前列腺特异性抗原（PSA）水平的相关性。
Cureus. 2024 Jun 30;16(6):e63548. doi: 10.7759/cureus.63548. eCollection 2024 Jun.
2
Intraoperative Tumor Detection Using Pafolacianine.术中使用帕拉福酰胺检测肿瘤。
Int J Mol Sci. 2022 Oct 25;23(21):12842. doi: 10.3390/ijms232112842.

本文引用的文献

1
Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.基于人群的前列腺特异性抗原筛查前列腺癌：欧洲泌尿外科学会 2019 年立场声明。
Eur Urol. 2019 Aug;76(2):142-150. doi: 10.1016/j.eururo.2019.04.033. Epub 2019 May 12.
2
Active surveillance in patients with a PSA >10 ng/mL.对前列腺特异性抗原（PSA）>10 ng/mL的患者进行主动监测。
Can Urol Assoc J. 2014 Sep;8(9-10):E702-7. doi: 10.5489/cuaj.2121.
3
The Prostate Health Index: a new test for the detection of prostate cancer.
前列腺健康指数：一种用于检测前列腺癌的新测试。
Ther Adv Urol. 2014 Apr;6(2):74-7. doi: 10.1177/1756287213513488.
4
Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).推进前列腺癌筛查辩论（前列腺癌特异性死亡率及相关风险）
Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063.
5
Prostate-specific antigen testing across the spectrum of prostate cancer.前列腺癌全谱中的前列腺特异性抗原检测。
Biomark Med. 2011 Aug;5(4):515-26. doi: 10.2217/bmm.11.53.
6
Prostatic specific antigen for prostate cancer detection.用于前列腺癌检测的前列腺特异性抗原。
Int Braz J Urol. 2009 Sep-Oct;35(5):521-9; discussion 530-2. doi: 10.1590/s1677-55382009000500003.
7
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.血清中前列腺特异性抗原的酶原形式可提高前列腺癌的检测率。
Clin Chem. 2004 Jun;50(6):1017-25. doi: 10.1373/clinchem.2003.026823. Epub 2004 Mar 30.
8
Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients.约旦患者前列腺特异性抗原（PSA）的年龄特异性参考范围。
Prostate Cancer Prostatic Dis. 2003;6(3):256-60. doi: 10.1038/sj.pcan.4500656.
9
Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL.游离/总前列腺特异性抗原比值是初始前列腺特异性抗原水平为4.1至10.0纳克/毫升的男性未来前列腺癌发病率的有力预测指标。
Urology. 2003 Apr;61(4):760-4. doi: 10.1016/s0090-4295(02)02427-5.
10
Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.游离前列腺特异性抗原百分比的测定有助于避免对直肠检查正常且总前列腺特异性抗原为4 - 10 ng/ml的男性进行不必要的活检。
Eur Urol. 2000 Mar;37(3):289-96. doi: 10.1159/000052358.